文献速递肝病消化道肿瘤与早癌

肝细胞癌合并门静脉癌栓患者是否适合肝移植?

Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
PubMed 文献 · J Hepatol · 2023-01-01

本文以辩论形式讨论肝细胞癌(HCC)合并门静脉癌栓(PVTT)患者是否适合肝移植(LT)。支持方认为成功降期后LT的生存获益远优于姑息性系统治疗;反对方指出证据质量受研究设计及患者特征、降期方案异质性限制,且预期生存仍低于公认LT阈值及米兰标准外其他移植患者水平。作者认为现有证据尚不足以让共识指南推荐该做法,期待更高质量证据和标准化降期方案后LT能更广泛适用。

要点

  • 支持LT的理由是成功降期后生存获益优于姑息性系统治疗。
  • 反对LT的理由包括证据质量受研究设计及患者特征、降期方案异质性限制。
  • 作者认为现有证据尚不足以让共识指南推荐该做法。

核心结论

  • 基于现有证据,共识指南推荐该做法似乎为时过早。
  • 作者希望随着更高质量证据和标准化降期方案的出现,LT可能很快更广泛地适用,包括这一临床需求高度未满足的人群。

研究设计与样本

  • 本文为辩论形式,讨论肝细胞癌合并门静脉癌栓患者是否适合肝移植。

主要发现

  • 支持方认为成功降期后LT在生存结局方面带来的临床获益远大于现有替代方案(姑息性系统治疗)。
  • 反对方认为LT证据质量受研究设计及患者特征与降期方案异质性限制。
  • 反对方认为该类患者预期生存仍低于公认的LT阈值,也低于米兰标准外其他接受移植患者达到的水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • LT证据质量受研究设计限制。
  • 患者特征存在异质性。
  • 降期方案存在异质性。
  • 该类患者预期生存仍低于公认的LT阈值,也低于米兰标准外其他接受移植患者达到的水平。
  • 作者认为基于现有证据,共识指南推荐该做法似乎为时过早。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this debate, the authors consider whether patients with hepatocellular carcinoma (HCC) and portal vein tumour thrombosis are candidates for liver transplantation (LT). The argument for LT in this context is based on the premise that, following successful downstaging treatment, LT confers a much greater clinical benefit in terms of survival outcomes than the available alternative (palliative systemic therapy). A major argument against relates to limitations in the quality of evidence for LT in this setting - in relation to study design, as well as heterogeneity in patient characteristics and downstaging protocols. While acknowledging the superior outcomes offered by LT for patients with portal vein tumour thrombosis, the counterargument is that expected survival in such patients is still below accepted thresholds for LT and, indeed, the levels achieved for other patients who receive transplants beyond the Milan criteria. Based on the available evidence, it seems too early for consensus guidelines to recommend such an approach, however, it is hoped that with higher quality evidence and standardised downstaging protocols, LT may soon be more widely indicated, including for this population with high unmet clinical need.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Soin A, Lesurtel M, Bhangui P, et al. Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation? J Hepatol. 2023. PMID: 37208099. doi:10.1016/j.jhep.2023.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。